Mynvax

India
Bengaluru, Karnataka, India, 560041

Company profile

Mynvax company profile

Mynvax is an Indian-based biotech startup that develops next-generation vaccines for influenza. In addition, the technology allows for very rapid, large-scale, and low-cost production of vaccines that could potentially be used to protect people when there is a pandemic. Mynvax, which was incubated at the Indian Institute of Science, was founded in 2017 by Raghavan Varadarajan and Gautham Nadig.

Business identity

Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$10M-$100M
Founded
2017-05-05

Headquarters

Postal code
560041
Country code
IN
Continent
Asia

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Total equity funding
$6.7M
Last funding
Series A / $2.6M / 2024-05-24
Last equity funding
Series A / $2.6M
Investors
8
Lead investors
3
Founders
2
Articles
12

Founders and investors

Founders

Gautam NadigRaghavan Varadarajan

Lead investors

AccelAjith SukumaranInviga Healthcare Fund

Investors

1CrowdAccelInviga Healthcare FundKotak Alternate Asset ManagersLVX Ventures